With the microbiota-based MRT™ drug platform, Rebiotix is on the forefront of a new era of medical therapies.
There is the potential to change the therapeutic landscape for Clostridium difficile (C. diff.) and for other conditions that result from disruption of the gut microbiota.
To achieve this goal, Rebiotix works closely with leading physicians in infectious disease and gastroenterology. Through collaboration, we have the potential to speed the development of new therapies.
We are currently working with physicians on studies assessing MRT™ drug platform for: